Table 1.
Patients’ clinical and histopathological characteristics (n = 68)
| Characteristics | No. case | LMS (n = 36) | ESS (n = 25) | MMMT (n = 7) |
|---|---|---|---|---|
| Age (years) | ||||
| <50 | 38 (55.8 %) | 20 | 17 | 1 |
| ≥50 | 30 (44.2 %) | 16 | 8 | 6 |
| Stage | ||||
| I | 36 (53.9 %) | 19 | 13 | 4 |
| II | 3 (4.4 %) | 3 | 0 | 0 |
| III | 22 (32.4 %) | 7 | 12 | 3 |
| IV | 7 (10.3 %) | 7 | 0 | 0 |
| Tumor size (cm) | ||||
| <5 | 30 (44.1 %) | 16 | 11 | 3 |
| ≥5 | 38 (55.9 %) | 20 | 14 | 4 |
| Pelvic lymphadenectomy | ||||
| Yes | 34 (50 %) | 17 | 13 | 4 |
| No | 34 (50 %) | 19 | 12 | 3 |
| Lymph node metastasis | ||||
| Positive | 24 (35.3 %) | 18 | 4 | 2 |
| Negative | 44 (64.7 %) | 33 | 9 | 2 |
| Surgical procedure | ||||
| TAH ± BSO/OT/PL/PLND | 8 (11.8 %) | 4 | 4 | 0 |
| TAH + BSO ±/PL/OT | 29 (42.6 %) | 17 | 12 | 0 |
| TAH + BSO + PL ± OT ± PLND | 31 (45.6 %) | 15 | 9 | 7 |
| Chemotherapy | 22 (32.4 %) | 13 | 9 | 0 |
| Radiotherapy | 4 (5.9 %) | 1 | 3 | 0 |
| Hormone therapy | 1 (1.5 %) | 0 | 1 | 0 |
| Chemotherapy and radiotherapy | 20 (29.4 %) | 10 | 3 | 7 |
| Chemotherapy and hormone therapy | 3 (4.4 %) | 1 | 2 | 0 |
| Radiotherapy and hormone therapy | 1 (1.5 %) | 0 | 1 | 0 |
| No adjuvant therapy | 17 (25 %) | 11 | 6 | 0 |
| Distant metastasis and recurrence | ||||
| Pelvic | 10 (14.7 %) | 6 | 3 | 1 |
| Pelvic and liver/lung | 6 (8.8 %) | 4 | 2 | 0 |
| Lung | 4 (5.9 %) | 3 | 1 | 0 |
| Other parts | 6 (8.8 %) | 5 | 1 | 0 |
| None | 42 (61.5 %) | 18 | 18 | 6 |
TAH total abdominal hysterectomy, BSO bilateral salpingo-oophorectomy, OT omentectomy, PL pelvic lymphadenectomy, PLND para-aortic lymph node dissection